Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
Pfizer’s Global Blood buy fails to Thrive
Inclacumab fails, and osivelotor is on hold.
Compass makes hay in bispecifics
Progress with three bispecific molecules is rewarded with a $120m equity raise.
